BioPharmSignal logoBioPharmSignal

Biotech News

MeiraGTx Announces Pricing of $100 Million Offering of Ordinary Shares

MeiraGTx (MGTX)MeiraGTxFinancing

LONDON and NEW YORK, April 16, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medicines company, today announced the pricing of an underwritten offering of 11,111,111 of its ordinary shares at an offering price of $9.00 per share.

Open original release

Related news

OTLKOutlook2026-05-28 20:00 EST

Outlook Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

EDITEditas Medicine2026-05-26 13:05 EST

Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering

TSHATaysha Gene Therapies2026-06-25 02:34 EST

Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

NTLAIntellia2026-04-29 11:00 EST

Intellia Therapeutics Announces Pricing of Public Offering of Common Stock

OTLKOutlook2026-04-23 20:05 EST

Outlook Therapeutics Announces Closing of $5.0 Million Registered Direct Offering

TSHATaysha Gene Therapies2026-06-24 20:01 EST

Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

NTLAIntellia2026-04-27 20:01 EST

Intellia Therapeutics Announces Proposed Public Offering of Common Stock

MGTXMeiraGTx2026-07-07 11:30 EST

MeiraGTx Announces $400 million Strategic Investment by Oberland Capital to Support Development and Commercialization of AAV2-hAQP1 and Botaretigene Sparoparvovec (bota-vec)

PASGPassage Bio2026-06-24 20:05 EST

Passage Bio and Remix Therapeutics Announce Merger Agreement

MGTXMeiraGTx2026-05-14 20:30 EST

MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

View all latest news

MeiraGTx

MeiraGTx is a gene-therapy company focused on ophthalmology, rare disease, and genetics-based medicines. Its platform aims to deliver durable therapies to difficult-to-treat diseases.

Recent company news

MGTXMeiraGTx2026-07-07 11:30 EST

MeiraGTx Announces $400 million Strategic Investment by Oberland Capital to Support Development and Commercialization of AAV2-hAQP1 and Botaretigene Sparoparvovec (bota-vec)

MGTXMeiraGTx2026-05-14 20:30 EST

MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

MGTXMeiraGTx2026-05-14 12:00 EST

MeiraGTx Reports First Quarter 2026 Financial and Operational Results

MGTXMeiraGTx2026-04-16 11:48 EST

MeiraGTx Announces Pricing of $100 Million Offering of Ordinary Shares

MGTXMeiraGTx2026-04-16 11:10 EST

MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP)

Stock data

Close
12.30 USD
Market cap
855.71M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States